Skip Navigation

U.S. Flag

Print Print   Download Reader Download   Text Enlarge text size Reduce text size Normal text size

Go to Text Version

HHS Recovery Act Recipient Reporting Readiness Tool

Step 4. Review and Copy the Grant Awards Data

TAGGS provides some – but not all – of the data needed for the Recipient Report. Recipients are responsible for directly collecting and reporting all required data to FederalReporting.gov. Data that HHS does not currently collect are highlighted in yellow. Do not copy this highlighted information. Please enter the appropriate data for your organization in these required fields. For assistance with entering these data please contact FederalReporting.gov.

You may capture the data HHS does provide by copying data from this screen and pasting it into the reporting format of your choice, such as the Excel spreadsheet template, the XML template, or by logging into the online form. For assistance with copying and pasting these data please contact our help desk at 866-814-5703.

 

Award Detail for: GROWTH AND CARCINOGENIC POTENTIAL IN THE POSTNATAL MAMMARY GLAND
MEDICAL UNIVERSITY OF SOUTH CAROLINA
DUNS Number: 183710748
19 HAGOOD AVE, SUITE 608
CHARLESTON, SC 29403-5120
Recipient Report: Grant or Loan
Prime Recipient

<
Reporting Information
Award Type Award Number Final Report
Grant 1R03HD060265-01A1 Recipient responsible for this data

Award Recipient Information
Recipient DUNS Number Recipient Account Number Recipient Congressional District
183710748 Recipient responsible for this data 1

Award Information
Funding Agency Code Awarding Agency Code Award Date
7529 7529 08-24-2009
Amount of Award Sub Account Number for Program Source (TAS)  
$ 73,750 Recipient responsible for this data
Program Source (TAS)* CFDA Number 
750840 93.701
Total Number of Sub Awards to Individuals Total Amount of Sub Awards to Individuals
Recipient responsible for this data Recipient responsible for this data
Total Number of Payments to Vendors less than $25,000/award Total Amount of Payments to Vendors less than $25,000/award
Recipient responsible for this data Recipient responsible for this data
Total Number of Sub Awards less than $25,000/award Total Amount of Sub Awards less than $25,000/award
Recipient responsible for this data Recipient responsible for this data
Award Description
DESCRIPTION (provided by applicant): Mammary development occurs in two distinct phases, an initial phase of modest growth (embryonic to puberty) and a later phase of robust expansion. Not surprisingly, studies on the early, relatively "quiescent" phase are greatly overshadowed by the latter. Nevertheless, changing conditions during the early phase have important consequences on later mammary development and carcinogenic potential. This was clearly identified when it was found that estrogenic exposure in 5-day estrogen-treated newborn mice resulted in a proliferative response, but one that occurred later at puberty. Paracrine estrogen receptor (ER1) stimulation elevates growth hormone-induced production and release of insulin-like growth factor 1 (IGF-I) and thereby induces an epithelial proliferative response, but the reason for the delay is unclear. Our published and preliminary results and those of others raise the possibility that the homeobox transcription factor HoxC6 may underlie this delayed response: 1) Mammary ductal trees in our HoxC6 deficient animals display a profound failure to undergo postnatal expansion; 2) In normal animals, HoxC6 is expressed in epithelium and stroma and stromal expression is repressed by estrogen; 3) HoxC6 is a direct transcriptional repressor of IGF binding protein 3 (IGFBP3), and IGFBP3 upregulation occurs in HoxC6-downregulated mammary epithelial cell lines and HoxC6 null mammary glands. In the latter case, we also observed downregulation of matrix metalloproteinases (MMPs) and upregulation of inhibitors of MMPs, indicating IGFBP3 stabilization. This would suggest that neonatal exposure to estrogen would indeed stimulate production of IGF-I (via ER1), but also repress HoxC6, resulting in an increase in IGFBP3 synthesis and stability. The presence of IGFBP3 would sequester and stabilize IGF-I in the stroma and blunt an immediate epithelial response. At puberty, ER1 hyper-stimulation would destabilize IGFBP3, thereby releasing stores of IGF-I for excessive growth/survival and ductal expansion. Excessive expansion of undifferentiated mammary epithelial stem cells being a link to risk. Our overall hypothesis is that HoxC6 mediates the estrogen-induced delay in mammary epithelial cell proliferation by de-repressing IGFBP3 expression, blunting IGF-I stromal-to-epithelial signaling in the early phase. This will be tested experimentally in one Specific Aim. The goal of AIM 1 is to define the mechanism by which HoxC6 modulates IGF-I stromal-to-epithelial signaling in the regulation of mammary epithelial growth/survival & branching. This will be accomplished using: 1) cell type-specific cultures; 2) whole organ cultures; and 3) in vivo models. In all studies, the impacts of estrogen exposure and HoxC6 expression status in mammary stroma and epithelium will be measured regarding IGF-I signaling, gene expression (IGF-I, HoxC6, IGFBP3, FGFR2) and cellular characteristics of growth/survival, migration, differentiation and branching. A practical goal of this study is to utilize HoxC6 gene expression levels in vitro as a surrogate for the assessment of anthropogenic and natural compounds that impact on postnatal mammary epithelial carcinogenic potential. PUBLIC HEALTH RELEVANCE: Early menarche and breast development are risk factors for breast cancer, which is the second leading cause of cancer-related deaths in women, and early exposure to natural and anthropogenic estrogens can profoundly sensitize the mammary gland to early development and cancer. In this study, we will test our model that early exposure to estrogens stimulate production of excess growth factor that is sequestered and stabilized and thereby elicits early menarche and hyper-stimulation of mammary growth/survival and expansion. The practical application of this work is toward the development of high throughput identification of bioactive compounds that promote or prevent breast carcinogenesis.

Project Information
Project Name or
Project/Program Title
Project Status Total Federal Amount ARRA Funds
Received/Invoiced
GROWTH AND CARCINOGENIC POTENTIAL IN THE POSTNATAL MAMMARY GLAND Recipient responsible for this data Recipient responsible for this data
Number of Jobs Description of Jobs Created
Recipient responsible for this data Recipient responsible for this data
Quarterly Activities/Project Description
Recipient responsible for this data
 
Activity Code (NAICS or NTEE-NPC)
1Recipient responsible for this data2Recipient responsible for this data
3Recipient responsible for this data4Recipient responsible for this data
5Recipient responsible for this data6Recipient responsible for this data
7Recipient responsible for this data8Recipient responsible for this data
9Recipient responsible for this data10Recipient responsible for this data
Total Federal Amount of ARRA
Expenditure
Total Federal ARRA
Infrastructure Expenditure
Infrastructure Contact Name
Recipient responsible for this data Recipient responsible for this data Recipient responsible for this data
Infrastructure Contact Email Infrastructure Contact Phone Infrastructure Contact Phone Ext.
Recipient responsible for this data Recipient responsible for this data Recipient responsible for this data
Infrastructure Contact Street Address 1 Infrastructure Contact Street Address 2 Infrastructure Contact Street Address 3
19 HAGOOD AVE, SUITE 608 Not Available Recipient responsible for this data
Infrastructure City Infrastructure State Infrastructure ZIP Code+4
CHARLESTON SC 29403-5120
Infrastructure Purpose and Rationale
Recipient responsible for this data

Primary Place of Performance
Street Address 1 Street Address 2 City
MSC 908 Recipient responsible for this data CHARLESTON
State Zip Code+4 Congressional District
SC 29425 1
Country  
US

Recipient Highly Compensated Officers
Prime Recipient Indication of Reporting Applicability # Officer Name Officer Compensation
Recipient responsible for this data 1 Recipient responsible for this data Recipient responsible for this data
2 Recipient responsible for this data Recipient responsible for this data
3 Recipient responsible for this data Recipient responsible for this data
4 Recipient responsible for this data Recipient responsible for this data
5 Recipient responsible for this data Recipient responsible for this data

This concludes the current search.
To begin a new search, return to the HHS Recovery Act Recipient Reporting Readiness Tool.

USE IN THE RECIPIENT REPORT

The information provided by this tool is baseline data that the Recipient should include in the Recipient Report that must be submitted to FederalReporting.gov beginning October 1, 2009. The data from this tool can be cut and pasted directly into the Recipient Report.